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A U.S. Payer PerspectiveThe report of the ISPOR 2012 Budget Impact Analysis Good
Practice II Task Force [1] updates the previous guidance published
in 2007 [2]. We review many budget impact analyses (BIAs) in our
practice and ﬁnd them to be of widely varying quality; thus, we
hope that this report will improve overall value and consistency
of the models we receive.
Clinical validity, transparency, and ﬂexibility are the most
important user requirements. Models based on unrealistic clin-
ical assumptions or clinical care pathways bearing little resem-
blance to those in the user’s setting have little or no value. The
report gives particular attention to emerging markets, reﬂecting
the growth of ISPOR membership in these countries. This grow-
ing diversity of user settings makes ﬂexibility even more
imperative.
The updated guidance reﬂects methodologic advance-
ments made since the last report. The clarity and speciﬁcity
of the new recommendations set expectations that, if fol-
lowed, will improve the ability of model developers to meet
today’s needs. BIA is usually designed for budget holders but
may be applied by others, such as health systems and policy-
makers. Hereafter, we refer to these parties collectively as
users.
Information from BIAs complements cost-effectiveness ana-
lysis. With increasingly tight budgets, payers face difﬁcult deci-
sions when evaluating expensive new technologies. Cost-
effectiveness of the new technology may set spending priorities,
but coverage decisions require an estimate of the resulting
expenditures and potential cost offsets. Budget holders need
both tools to accurately predict the clinical and ﬁnancial impact
of formulary listing and coverage decisions and manage the
health of their populations. In the United States, actuaries need
this information to calculate the following year’s insurance
premiums.
The analytic framework section is clearer and more detailed
than its predecessor. Key points include: 1) ﬂexible user inputs to
adapt to setting and perspective, 2) transparency and simplicity,
3) estimating target populations, 4) predicting changes in inter-
vention mix with introduction of the new treatment, and 5)
estimating cost offsets. This guidance should be followed closely
to produce more meaningful models for users.
The report’s discussion of data and data sources offers key
recommendations to both BIA creators and users. Data must be
relevant to and ideally drawn from the user’s population. If
local data are unavailable, they can be estimated through the
use of credible sources clearly referenced and readily accessible
to the user. Relevant cost data should be decomposed and
presented in a manner that the user can readily compare toial support: The authors have no other ﬁnancial rcosts actually incurred by their population. Summarized or
“rolled-up” treatment costs are insufﬁcient for this purpose
and should cause the user to question the transparency of the
BIA. Furthermore, for a model to reﬂect the actual ﬁnancial
ﬂows of private sector health systems, the users must be able
to enter actual costs into the models. This means that the
model developers should leave behind a working copy of the
model.
Modeling reports should clearly and succinctly describe meth-
ods, epidemiology, disease burden, and clinical impact. An inter-
active, easily understood version of the model should be provided
by using common spreadsheet software, rather than requiring
the user to purchase special software. Graphs and ﬁgures facil-
itate user understanding and support presentation of the results
by the user to others. Tornado diagrams are very useful to
identify key model drivers, and so users can focus on accurate
estimation of these inputs. We recommend that users reject any
BIA lacking such documentation because such omissions directly
call into question the overall transparency and validity of the
model.
The task force recommends that model developers not
model off-label use of the new product routinely but provide
this additional analysis on user request; however, they agree
that budget models are descriptive rather than normative.
Inclusion of off-label use should not be construed as advocat-
ing it, because the models merely depict existing practice
patterns without judging appropriateness. We encourage
users to request it routinely because off-label use is to be
expected in most cases. A model that does not include it is
unlikely to reﬂect the user’s setting realistically. For this
reason, the Academy of Managed Care Pharmacy’s Format for
Formulary Submissions includes a speciﬁc request for “signiﬁ-
cant off-label uses and potential new indications being stu-
died” [3].
It cannot be overemphasized that the usefulness of an
economic model to a user is limited by the accuracy with which
it represents the realities of clinical practice in that user’s setting.
Common threats to validity include unrealistic assumptions
about clinical care pathways, frequency of certain diagnostic
tests, and patient adherence outside of controlled trials. Models
based on unrealistic clinical assumptions have little or no value
to us.
With these caveats in mind, we believe that following the
guidance provided by the task force will meaningfully improve
the validity, transparency, and ﬂexibility of BIAs provided to
payers and other users in an increasing variety of different
settings.elationships to disclose.
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